The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...
Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis. Verzenio (abemaciclib) is a CDK4 and 6 ...
All of these are medications in Lilly's weight loss portfolio. However, another star performer throughout 2024 was Verzenio -- Lilly's main oncology treatment. For the nine months ended Sept.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback